Tailored Probiotic Use: Saccharomyces Boulardii's Possible Role in Managing Giardia Infections in Dobermans
You are probably here because your veterinarian diagnosed your Doberman with Giardia, and you heard somewhere on the internet about something almost none of us can pronounce: Saccharomyces boulardii (S. boulardii). S. boulardii is a non-pathogenic yeast (Rakel, 2018) and it sets itself apart from other probiotics not only due to its resilience, but also broad-spectrum properties that many call therapeutic. The issue is, while S. boulardii may offer a promising adjunct therapy for gastrointestinal issues such as Giardia infections, the research is limited in dogs. Below we will give you an honest review of S. boulardii and let you decide for yourself if you want to give it a go.
Why S. boulardii is Different from Other Probiotics
In the world of countless products for your dog’s gut, S. boulardii features a bit of a different profile amongst probiotics. Unlike common bacterial probiotics, S. boulardii is a yeast, which inherently makes it more resistant to gastrointestinal conditions such as acidity and the presence of antibiotics that might disrupt bacterial flora (McFarland, 2010). Its potential mechanisms of action, as we will discuss below, include inhibition of pathogen adherence, immune modulation, and enhancement of the intestinal barrier, all of which can be critical factors in managing digestive health in dogs, especially if your Doberman has a sensitive GI system to begin with.
Mechanisms of Action
This is where it will get a bit technical, but fear not, we will explain.
Inhibition of Pathogen Adherence: Human research suggests that S. boulardii produces substances that can inhibit the growth of harmful organisms like Giardia by interfering with their ability to adhere to the gut lining (Ribeiro et al., 2018, 2021; Roskens & Erlandsen, 2002).
In plain English: S. boulardii may help make it harder for Giardia to cling to your Doberman’s gut lining.
Immune System Support: In mice, S. boulardii increased total small-intestinal IgA and anti-toxin A IgA after Clostridium difficile toxin A exposure (Qamar et al., 2001). In a small canine study limited to healthy adult American Staffordshire Terriers, S. boulardii affected fecal immune and inflammatory markers, including reduced IgA and calprotectin, suggesting immune modulation rather than simple “immune boosting” (Meineri et al., 2022). Broader anti-inflammatory and immune-modulating effects are also supported by mechanistic research (Stier & Bischoff, 2016; Pothoulakis, 2009), while trophic effects on intestinal function have been described as well (Moré & Vandenplas, 2018).
In simplified words without dragging you through the usual immune-marker alphabet soup, S. boulardii does not just hit an “immune boost” button; it may help the gut’s immune response behave in a more balanced way.
Supporting the Intestinal Barrier:Human and experimental research suggests that S. boulardii may help preserve or restore the intestinal barrier. One possible mechanism is an increase in short-chain fatty acids, especially butyrate, which help nourish colon cells and support tight junction integrity, but this has not been shown directly in dogs with Giardia (Schneider et al., 2005; Terciolo et al., 2019).
Think of the gut lining as a fence made of tiny panels: the intestinal cells are the panels, and the tight junctions are the seals between them. S. boulardii may help support those cells and seals, which may help keep the barrier intact, but we do not yet know whether this works the same way in dogs with Giardia.
S. boulardii in the Treatment of Giardia Infections in Dobermans
Without getting buried in the disease mechanisms, Giardiasis is caused by the protozoan parasite Giardia lamblia. It is the most common cause of waterborne disease caused diarrhea in the USA (Adam, 2001) that leads to diarrhea and malabsorption in humans (Feng & Xiao, 2011) and dogs (Robertson, 2025). When it comes to Giardia infections, the administration of S. boulardii alongside traditional treatments like metronidazole has shown promise in improving treatment outcomes. But this is where online cheerleading often overstates the facts, especially for dogs, because the existing research does not prove a clear benefit yet.
One study showed that in human patients, the combination of S. boulardii with metronidazole significantly reduced the presence of Giardia cysts compared to treatment with metronidazole alone (Besirbellioglu et al., 2006). Combined with the aforementioned Meineri et al.’s (2022) limited findings in dogs, the research may suggest potential benefit for dogs, and, hence, Dobermans, but just because something connects and looks plausible on paper does not mean it will hold up under further study and under specific conditions.
Gerbil research:
There is also some experimental research in gerbils, which adds another piece to the puzzle. However, gerbils are not dogs, and your Doberman has every right to be offended by the comparison. Yet, these studies still help build the broader body of work around S. boulardii and Giardia and they give researchers possible directions.
In two experimental gerbil studies, Ribeiro et al. (2018; 2021) found that Saccharomyces boulardii reduced Giardia lamblia parasite burden and helped protect intestinal mucosal structure. The Ribeiro et al. (2018) study reported an approximately 70% reduction in parasite load when S. boulardii was given before infection and continued through the experiment, while the 2021 study reported an approximately 90% reduction in parasite load when S. boulardii, alone or with metronidazole, was used after infection had been established.
These findings help researchers form better hypotheses and give them a clearer direction for future studies. But, even if we sound like a broken record, gerbil studies do not prove that the same results will happen in dogs with Giardia, nor do they prove that S. boulardii reliably improves treatment outcomes in Dobermans.
Now, do not get us wrong: the evidence we do have is not meaningless. S. boulardii has several biologically plausible mechanisms, human research has shown some benefit when used alongside metronidazole, experimental gerbil studies point in an interesting direction, and limited canine research suggests it can influence gut immune and inflammatory markers in healthy dogs. That is enough to make it worth discussing, not enough to declare it a proven Giardia treatment for Dobermans.
With that being said, the possible role of S. boulardii in managing Giardia infections is promising because several pieces of the research point toward multifaceted actions:
Limiting parasite attachment: In gerbil models, S. boulardii reduced Giardia parasite burden and mucosal attachment, possibly through increased mucus production (Ribeiro et al., 2018, 2021; Roskens & Erlandsen, 2002). Remember, for the sake of your relationship with your Doberman, do not compare them to a gerbil or, dare we say it, to yourself.
Supporting mucosal defenses: In gerbils, S. boulardii increased intraepithelial lymphocytes and reduced Giardia burden, suggesting support for local intestinal defense (Ribeiro et al., 2018). However, again, direct canine evidence remains limited, and a human study found no change in intestinal lymphocyte phenotypes or small-intestinal IgA after three weeks of S. boulardii (Jahn et al., 1996).
Supporting recovery of gut function: Limited human Giardia evidence suggests that S. boulardii may support recovery when used alongside standard treatment (Besirbellioglu et al., 2006), including improved parasite clearance and stool patterns (Castañeda Guillo et. al., as cited in Kelesidis & Pothoulakis, 2012), but, again, direct canine evidence is limited.
More Scientific Evidence Supporting S. boulardii
This next piece is not Giardia-specific research, so let us not pretend it is. It does, however, add to the broader gut-health picture around S. boulardii. Different studies in different gastrointestinal problems can help researchers see patterns, ask better questions, and figure out where S. boulardii may or may not be useful. Annoyingly, science often works by building a pile of puzzle pieces before anyone gets to see the full picture.
Part of the puzzle is that there is also limited research that may point towards S. boulardii’s possible role in managing some gastrointestinal disorders. For instance, a systematic review with meta-analysis of human studies found that S. boulardii effectively reduces the risk of antibiotic-associated diarrhea in both children and adults (Szajewska & Kołodziej, 2015), and improved Helicobacter pyloriinfection eradication rates when used as an adjunct to standard Helicobacter pylorieradication therapy (Szajewska et al., 2015). Although more research is needed, such findings highlight its potential utility in veterinary applications, including its use in Dobermans.
Let’s conclude with the understanding that integrating S. boulardii into a Giardia treatment regimen could enhance recovery and overall gastrointestinal health, but because the research in dogs is very limited, no one can say for sure how effective S. boulardii really is as an add-on treatment for Giardia in dogs. Because every dog can have a different risk profile, always consult with a veterinarian to tailor the probiotic use to your Doberman's specific health context and needs. In other words, you should never simply add a supplement to your dog’s care without talking to your veterinarian.
References
Adam R. D. (2001). Biology of Giardia lamblia. Clinical Microbiology Reviews, 14(3), 447–475. https://doi.org/10.1128/CMR.14.3.447-475.2001
Besirbellioglu, B. A., Ulcay, A., Can, M., Erdem, H., Tanyuksel, M., Avci, I. Y., Araz, E., & Pahsa, A. (2006). Saccharomyces boulardii and infection due to Giardia lamblia. Scandinavian Journal of Infectious Diseases, 38(6-7), 479–481. https://doi.org/10.1080/00365540600561769
Feng, Y., & Xiao, L. (2011). Zoonotic potential and molecular epidemiology of Giardia species and giardiasis. Clinical microbiology reviews, 24(1), 110–140. https://doi.org/10.1128/CMR.00033-10
Jahn, H. U., Ullrich, R., Schneider, T., Liehr, R. M., Schieferdecker, H. L., Holst, H., & Zeitz, M. (1996). Immunological and trophical effects of Saccharomyces boulardii on the small intestine in healthy human volunteers. Digestion, 57(2), 95–104. https://doi.org/10.1159/000201320
Qamar, A., Aboudola, S., Warny, M., Michetti, P., Pothoulakis, C., LaMont, J. T., & Kelly, C. P. (2001). Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice. Infection and Immunity, 69(4), 2762–2765. https://doi.org/10.1128/IAI.69.4.2762-2765.2001
Kelesidis, T., & Pothoulakis, C. (2012). Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders. Therapeutic advances in gastroenterology, 5(2), 111–125. https://doi.org/10.1177/1756283X11428502
Meineri, G., Martello, E., Atuahene, D., Miretti, S., Stefanon, B., Sandri, M., Biasato, I., Corvaglia, M. R., Ferrocino, I., & Cocolin, L. S. (2022). Effects of Saccharomyces boulardii supplementation on nutritional status, fecal parameters, microbiota, and mycobiota in breeding adult dogs. Veterinary Sciences, 9(8), 389. https://doi.org/10.33
McFarland L. V. (2010). Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World Journal of Gastroenterology, 16(18), 2202–2222. https://doi.org/10.3748/wjg.v16.i18.2202
Moré M.I., Vandenplas, Y. (2018). Saccharomyces boulardii CNCM I-745 improves intestinal enzyme function: A trophic effects review. Clinical Medicine Insights: Gastroenterology, 11, 1179552217752679. DOI: 10.1177/1179552217752679
Pothoulakis, C. (2009). Review article: Anti-inflammatory mechanisms of action of Saccharomyces boulardii. Alimentary Pharmacology & Therapeutics, 30(8):826–833. https://doi.org/10.1111/j.1365-2036.2009.04102.x
Rakel, D. (2017). Integrative medicine (4th ed.). Elsevier
Ribeiro, M. R. S., Oliveira, D. R., Oliveira, F. M. S., Caliari, M. V., Martins, F. S., Nicoli, J. R., Torres, M. F., Andrade, M. E. R., Cardoso, V. N., & Gomes, M. A. (2018). Effect of probiotic Saccharomyces boulardii in experimental giardiasis. Beneficial Microbes, 9(5), 789–797. https://doi.org/10.3920/BM2017.0155
Ribeiro, M. R. S., Oliveira, D. R., Caliari, M. V., Cara Machado, D. C., Andrade, M. E. R., Cardoso, V. N., dos Santos Martins, F.,
Robertson, L. J. (2025). Giardiasis in animals. https://www.merckvetmanual.com/digestive-system/giardiasis-giardia/giardiasis-in-animals?gclsrc=aw.ds&gad_source=1&gad_campaignid=18706620188&gbraid=0AAAAADGnyn0V9PkPtqfaGMk9pFrz03VX0&gclid=CjwKCAjwntHPBhAaEiwA_Xp6RktyYoTV85Ra--iy5wFIW28u3ZHc-NZRK86HiARmN6gOBG8Uo-31DhoCeQ4QAvD_BwE
Roskens, H., & Erlandsen, S. L. (2002). Inhibition of in vitro attachment of Giardia trophozoites by mucin. The Journal of Parasitology, 88(5), 869–873. https://doi.org/10.1645/0022-3395(2002)088[0869:IOIVAO]2.0.CO;2
Schneider, S. M., Girard-Pipau, F., Filippi, J., Hebuterne, X., Moyse, D., Hinojosa, G. C., Pompei, A., & Rampal, P. (2005). Effects of Saccharomyces boulardii on fecal short-chain fatty acids and microflora in patients on long-term total enteral nutrition. World Journal of Gastroenterology, 11(39), 6165–6169. https://doi.org/10.3748/wjg.v11.i39.6165
Stier, H., & Bischoff, S. C. (2016). Influence of Saccharomyces boulardiiCNCM I-745on the gut-associated immune system. Clinical and Experimental Gastroenterology, 9, 269–279. https://doi.org/10.2147/CEG.S111003
Szajewska, H., & Kołodziej, M. (2015). Systematic review with meta-analysis: Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea. Alimentary Pharmacology & Therapeutics, 42(7), 793–801. https://doi.org/10.1111/apt.13344
Szajewska, H., Horvath, A., & Kołodziej, M. (2015). Systematic review with meta-analysis: Saccharomyces boulardii supplementation and eradication of Helicobacter pylori infection. Alimentary Pharmacology & Therapeutics, 41(12), 1237–1245. https://doi.org/10.1111/apt.13214
Terciolo, C., Dapoigny, M., Andre, F., & Buret, A. G. (2019). Beneficial effects of Saccharomyces boulardii CNCM I-745 on clinical disorders associated with intestinal barrier disruption. Clinical and Experimental Gastroenterology, 12, 67–82. https://doi.org/10.2147/CEG.S181590
Disclaimer: The information provided in this article is for educational and informational purposes only and is not intended as a substitute for advice from your veterinarian or other healthcare professional. You should not use this information to diagnose or treat a health problem or disease or prescribe any medication or other treatment. Always consult with your veterinarian or other qualified healthcare provider before making any changes to your pet's healthcare regimen, especially if they have or suspect they may have a health problem. The author and publisher of this article are not responsible for any adverse effects or consequences resulting from the use of any suggestions, products, or procedures mentioned in this article. The use of this information is at the reader's discretion and risk.
Article last update: 2026, July
